Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 34203 - uncoated femoral stem prosthesis, modular - made of cocrmo, with sandblasted surface for use with bone cement. have the mutars fit (diam 16 mm h7g6) and serration (72 teeth) which allows an adjustment of the antetorsion angle in 5 degree steps. the stem is curved to suit the femur?s physiological antecurvature. it has a hexagonal cross section for rotation stability and collar at the proximal end to prevent subsidence. from length 160mm the stems have 5mm diameter distal bore holes for additional fixation with cortical screws. a femoral stem used in cases of major bone loss to support a hip, knee or diaphysis replacement prosthesis and provide primary fixation to the bone. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 34190 - uncoated hip femur prosthesis, modular - composed of titanium alloy tial6v4. proximal femur component of the mutars (modular universal tumor and revision system) system in two different lengths of 50 mm and 70 mm with taper (12/14), with retention rings for fixation of the attachment tube and various stems. the treatment can be adjusted with the use of the extension pieces of 20 mm increments. the proximal femur allows the adjustment of the antetorsion angles in 5 degree increments. proximal femoral replacement component indicated for tumours in the area of the proximal femur or other major bone defects including hip joint arthroplasty as hemi prosthesis or total hip replacement. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 34190 - uncoated hip femur prosthesis, modular - tial6v4 alloy with sand blasted surface. on the lateral surface a porous structure is provided for better bone ingrowth. trochanter major-like curvature for attachment of trochanteric bone and/or soft tissue with various lateral and medial suture holes. connects with other mutars components through a precise female cylindrical connection with serrated teeth (72) to provide rotational stability and allow for intra-operative adjustment of the femoral antetorsion angle in 5 degree increments. a hip joint replacement component of the mutars system that replaces the proximal part of the femur. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis.

Israel - English - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate - film coated tablets - estradiol as hemihydrate 2 mg - estradiol - estradiol - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy.the experience treating women older than 65 years is limited.

Israel - English - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate - film coated tablets - estradiol as hemihydrate 1 mg - estradiol - estradiol - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy.the experience treating women older than 65 years is limited.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ethinylestradiol 30ug; levonorgestrel 150ug; ethinylestradiol 30ug; levonorgestrel 150ug - tablet - 30mcg/150mcg - active: ethinylestradiol 30ug levonorgestrel 150ug excipient: calcium carbonate glycerol glycol/butylene glycol montanate iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate povidone   purified talc   purified water starch sucrose titanium dioxide calcium carbonate erythrosine montangylycol wax (wax e pharma) (dab) lactose monohydrate macrogol 6000 magnesium stearate ponceau 4r povidone   purified talc   starch sucrose active: ethinylestradiol 30ug levonorgestrel 150ug excipient: calcium carbonate carnauba wax white wax, polishing lactose monohydrate macrogol 6000 magnesium stearate povidone   purified talc   purified water starch sucrose calcium carbonate erythrosine montangylycol wax (wax e pharma) (dab) macrogol 6000 magnesium stearate ponceau 4r povidone purified talc starlac sucrose calcium carbonate erythrosine wax e pharma lactose macrogol 6000 magnesium stearate maize starch ponceau 4r povidone   purified talc   purified water sucrose - monofeme is indicated for prevention of pregnancy.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; indigo carmine; macrogol 400 - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 1.03 mg (equivalent: estradiol, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red; propylene glycol - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

Malta - English - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - dydrogesterone, estradiol - film-coated tablet - dydrogesterone 2.5 mg estradiol 0.5 mg - sex hormones and modulators of the genital system

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

the female health company , united kingdom - female condoms -